All In Biotech

Drug Trial Radar · NCT04330664

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2

Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Apr 7, 2020

Primary completion

Jul 29, 2022

Study completion Feb 24, 2025

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Novartis
First posted
Apr 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

Conditions

  • Advanced Cancer
  • Metastatic Cancer
  • Malignant Neoplastic Disease

Interventions

  • MRTX849Drug

    KRAS G12C Inhibitor

  • TNO155Drug

    SHP2 Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.Time frame: 20 months
  2. Evaluate the pharmacokinetics of MRTX849 and TNO155Time frame: 20 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 002-805

    Los Angeles, California

  • Local Institution - 002-803

    Orange, California

  • Local Institution - 002-828

    Chicago, Illinois

  • Local Institution - 002-942

    Wichita, Kansas

  • Local Institution - 002-804

    Boston, Massachusetts

  • Local Institution - 002-808

    Boston, Massachusetts

  • Local Institution - 002-811

    Novi, Michigan

  • Local Institution - 002-809 D

    City of Saint Peters, Missouri

  • Local Institution - 002-809 B

    Creve Coeur, Missouri

  • Local Institution - 002-809 A

    St Louis, Missouri

  • Local Institution - 002-809 C

    St Louis, Missouri

  • Local Institution - 002-809

    St Louis, Missouri

  • Local Institution - 002-809 E

    St Louis, Missouri

  • Local Institution - 002-813

    New York, New York

  • Local Institution - 002-806

    New York, New York

  • Local Institution - 002-801

    San Antonio, Texas

  • Local Institution - 002-810

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.